HIM
SUPN icon

Hillsdale Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Hillsdale Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.82M Buy
+103,680
New +$4.98M 0.11% 240
2025
Q2 		– Sell
-180
Closed -$5.89K – 708
2025
Q1 		$5.89K Buy
+180
New +$6.38K ﹤0.01% 558

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Hillsdale Investment Management's SUPN Position: Q2 2026 in Review

Hillsdale Investment Management opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2026: 103,680 shares worth $4.82M. The stake represents 0.11% of the portfolio and ranks #240 among its holdings. This is a return to the name: Hillsdale Investment Management previously reported a position in SUPN as recently as Q1 2025.

Hillsdale Investment Management first reported a position in SUPN in Q1 2025 and has held it in 2 quarters since. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Hillsdale Investment Management held 103,680 shares of Supernus Pharmaceuticals worth $4.82M as of Q2 2026.
  • Supernus Pharmaceuticals was a new Hillsdale Investment Management position in Q2 2026.
  • Supernus Pharmaceuticals made up 0.11% of Hillsdale Investment Management's portfolio in Q2 2026, its #240 holding.
  • Hillsdale Investment Management first reported a position in Supernus Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.